NCT04914897 2025-10-02
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
Sanofi
Phase 2 Terminated
Clinical Trials
14 trialsNCT02863055 2025-09-19
NEMO
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
NCT05563272 2025-07-10
STARBURST
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 2 Terminated
NCT03502746 2024-05-14
Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT02004028 2024-02-20
Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants
Verastem, Inc.
Phase 2 Terminated
NCT00003508 2021-04-27
Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma
Burzynski Research Institute
Phase 2 Terminated
NCT00859495 2020-08-25
Trimodal Lung-Sparing Treatment of Pleural Mesothelioma
Columbia University
Phase 2 Terminated
NCT02357147 2020-03-17
ARTEMIS
Morphotek
Phase 2 Terminated
NCT03175172 2019-04-04
Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)
Aduro Biotech, Inc.
Phase 2 Terminated
NCT00895648 2017-05-04
Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma
University Health Network, Toronto
Phase 2 Terminated
NCT01870609 2017-01-30
COMMAND
Verastem, Inc.
Phase 2 Terminated
NCT01861301 2016-10-24
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00165503 2016-09-09
Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT00027508 2015-02-24
Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma
PharmaMar
Phase 2 Terminated